Loading
A phase 2 trial of Pembrolizumab in triple-negative breast cancer, run by Hoffmann-La Roche, active and no longer recruiting.
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer is a phase 2 interventional study registered as NCT05852691 by Hoffmann-La Roche, with 83 participants enrolled, started 2023-07-18 and due to reach its primary completion in 2026-10-19. Interventions recorded: Tobemstomig, Pembrolizumab and Nab-Paclitaxel.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Flatiron Health (Roche), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/